<DOC>
	<DOCNO>NCT00742885</DOCNO>
	<brief_summary>This trial ass immunogenicity safety elicit adjuvanted GSK Biologicals ' ( pre- ) pandemic influenza candidate vaccine healthy Japanese adult .</brief_summary>
	<brief_title>Immunogenicity Safety GSK Biologicals ' ( Pre- ) Pandemic Influenza Candidate Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Japanese male female adult 20 64 year age time first vaccination , inclusive . Good general health assess medical history physical examination . Access consistent mean telephone contact , may either home workplace , land line mobile , NOT pay phone multipleuser device . Written inform consent obtain subject . Comprehension study requirement , express availability require study period , ability attend schedule visit . Subjects investigator believe comply requirement protocol enrol study . Presence significant acute chronic , uncontrolled medical psychiatric illness . Presence evidence substance abuse neurological psychiatric diagnosis , although stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Diagnosed cancer , treatment cancer within 3 year . Presence axillary temperature &gt; = 37.5 Â°C , acute symptom great `` mild '' severity schedule date first vaccination . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection . Receipt systemic glucocorticoid within 1 month study enrolment , cytotoxic immunosuppressive drug within 6 month study enrolment . Any significant disorder coagulation treatment Coumadin derivatives heparin . Administration register vaccine within 30 day study enrolment plan administration within first vaccination blood sample Day 42 within 30 day prior blood sample Day 182 . Use investigational nonregistered product within 30 day prior study enrolment plan use study period . History previous H5N1 vaccination , history H5N1 influenza infection . Receipt immunoglobulins and/or blood product within 6 month study enrolment plan administration product study period . Any known suspected allergy constituent influenza vaccine component use manufacturing process study vaccine , history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Known pregnancy positive urine betahuman chorionic gonadotropin test result prior time first vaccination . Lactating nursing . Women childbearing potential lack history reliable contraceptive practice . The provision history NOT replace requirement perform , obtain negative result pregnancy urine test prior treatment ; woman urine pregnancy test regardless status . Known receipt analgesic antipyretic medication day treatment ( Day 0 ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Pandemic Influenza</keyword>
</DOC>